CLPTM1L and pancreatic neoplasm: This is consistent with findings from other malignancies, such as lung and pancreatic cancers, where CLPTM1L has been implicated in promoting tumor growth through resistance to apoptosis and activation of the PI3K/Akt pathway [15, 16].